McKesson Corporation logo
McKesson Corporation (MCK)
Compare

McKesson Corporation (MCK) Quick Ratio (Acid-Test): 0.49

popular:market cap|pe ratio|revenue|price history|total return

Is McKesson Corporation’s quick ratio (acid-test) high or low?

McKesson Corporation's quick ratio (acid-test) of 0.49 is in line with its 5-year average of 0.53, near the low end of its 5-year range (0.49–0.59).

As of Saturday, June 20, 2026. 3.92% below its 12-month average of 0.51.

Current Ratio|Debt to Equity|P/FCF Ratio|All Metrics

MCK Quick Ratio (Acid-Test) Chart

MCK Quick Ratio (Acid-Test)
0.49-7.55% 1Y
Zoom

MCK Average Quick Ratio (Acid-Test) Chart

MCK Current vs Average Quick Ratio (Acid-Test) Chart

MCK Quick Ratio (Acid-Test) Metrics

QUICK RATIO (ACID-TEST)

0.49

QUICK RATIO (ACID-TEST) AVG TTM

0.51

QUICK RATIO (ACID-TEST) AVG 3Y

0.51

QUICK RATIO (ACID-TEST) AVG 5Y

0.53

QUICK RATIO (ACID-TEST) AVG 10Y

0.57

QUICK RATIO (ACID-TEST) AVG 15Y

0.59

QUICK RATIO (ACID-TEST) AVG 20Y

0.61

CURRENT VS TTM AVG

-3.92%

CURRENT VS 3Y AVG

-3.92%

CURRENT VS 5Y AVG

-8.13%

CURRENT VS 10Y AVG

-13.34%

CURRENT VS 15Y AVG

-17.12%

CURRENT VS 20Y AVG

-19.23%

MCK Competitors' Quick Ratio (Acid-Test)

NAMEMARKET CAPQUICK RATIO (ACID-TEST)TTM3Y5Y
McKesson Corporation (MCK)$87.88B0.490.510.510.53
Elevance Health Inc. (ELV)vs ›$84.37B1.241.171.081.07
HCA Healthcare, Inc. (HCA)vs ›$83.23B0.730.850.971.05
Medtronic plc (MDT)vs ›$101.86B1.621.521.601.67
Cigna Corporation (CI)vs ›$73.88B0.720.720.680.69
Boston Scientific Corporation (BSX)vs ›$67.32B1.080.860.891.02
Bristol-Myers Squibb Company (BMY)vs ›$110.27B1.141.151.191.27
Regeneron Pharmaceuticals, Inc. (REGN)vs ›$62.84B3.393.674.143.76
Vertex Pharmaceuticals Incorporated (VRTX)vs ›$114.63B2.462.413.313.62
Stryker Corporation (SYK)vs ›$118.00B1.211.271.131.20

Liquidity Comparison

Quick Ratio

0.49

Excludes inventory

Current Ratio

0.85

Includes inventory

McKesson Corporation Quick Ratio (Acid-Test) Formula & Definition

Quick Ratio = (Current Assets − Inventory) / Current Liabilities

The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

McKesson Corporation Quick Ratio (Acid-Test) FAQ

What is the quick ratio (acid-test) for McKesson Corporation (MCK)?
The quick ratio (acid-test) for MCK stock is 0.49.
Is McKesson Corporation's quick ratio (acid-test) high or low?
McKesson Corporation's quick ratio (acid-test) of 0.49 is in line with its 5-year average of 0.53, near the low end of its 5-year range (0.49–0.59).
What is the TTM average quick ratio (acid-test) for McKesson Corporation (MCK)?
The TTM average quick ratio (acid-test) for MCK stock is 0.51.
What is the 3Y average quick ratio (acid-test) for McKesson Corporation (MCK)?
The 3Y average quick ratio (acid-test) for MCK stock is 0.51.
What is the 5Y average quick ratio (acid-test) for McKesson Corporation (MCK)?
The 5Y average quick ratio (acid-test) for MCK stock is 0.53.
What is the 10Y average quick ratio (acid-test) for McKesson Corporation (MCK)?
The 10Y average quick ratio (acid-test) for MCK stock is 0.57.
What is the 15Y average quick ratio (acid-test) for McKesson Corporation (MCK)?
The 15Y average quick ratio (acid-test) for MCK stock is 0.59.
What is the 20Y average quick ratio (acid-test) for McKesson Corporation (MCK)?
The 20Y average quick ratio (acid-test) for MCK stock is 0.61.

McKesson Corporation Quick Ratio (Acid-Test) History

DATEQUICK RATIO (ACID-TEST)
2026-03-310.49
2025-03-310.53
2024-03-310.51
2023-03-310.51
2022-03-310.57
2021-03-310.59
2020-03-310.60
2019-03-310.58
2018-03-310.57
2017-03-310.61
2016-03-310.66
2015-03-310.67
2014-03-310.65
2013-03-310.60
2012-03-310.62
2011-03-310.70
2010-03-310.71
2009-03-310.65
2008-03-310.57
2007-03-310.64
2006-03-310.71
2005-03-310.66
2004-03-310.66
2003-03-310.66
2002-03-310.62
2001-03-310.62
2000-03-310.75
1999-03-310.62
1998-03-310.59
1997-03-310.57

Related Metrics

Current RatioDebt to EquityP/FCF RatioAll Metrics

About McKesson Corporation

McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.

Irving, TX
44,000 employees
www.mckesson.com
Healthcare / Medical - Distribution
Sector
Healthcare
Industry
Medical - Distribution
CEO
Brian S. Tyler
View full financials